Can We Rationalize Oral Drug Exposure Following Bariatric Surgery to Meet the Pharmacotherapeutic Needs of a Growing Patient Population? Commentary on: “Lithium Toxicity Following Roux-en-Y Gastric Bypass”
Restricted accessResearch articleFirst published online June, 2014
Can We Rationalize Oral Drug Exposure Following Bariatric Surgery to Meet the Pharmacotherapeutic Needs of a Growing Patient Population? Commentary on: “Lithium Toxicity Following Roux-en-Y Gastric Bypass”
DarwichAS, HendersonK, BurginA, et al.Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol, 2012; 74:774–787.
5.
MaloneM, Alger-MayerSA. Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother, 2005; 39:637–642.
6.
ElderKA, WolfeBM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology, 2007; 132:2253–2271.
7.
AmidonGL, LennernasH, ShahVP, CrisonJR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 1995; 12:413–420.
8.
Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Rockville, MD: FDA, 2000.
9.
BenetLZ, BroccatelliF, OpreaTI. Bddcs applied to over 900 drugs. AAPS J, 2011; 13; 519–547.
10.
LindenbergM, KoppS, DressmanJB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm, 2004; 58:265–278.
11.
SmithCD, HerkesSB, BehrnsKE, FairbanksVF, KellyKA, SarrMG. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg, 1993; 218:91–96.
12.
BehrnsKE, SmithCD, SarrMG. Prospective evaluation of gastric acid secretion and cobalamin absorption following gabtric Bypass for clinically severe obesity. Dig Dis Sci, 1994; 39:315–320.
13.
SeamanJS, BowersSP, DixonP, SchindlerL. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics, 2005; 46:250–253.
14.
HorowitzM, CookDJ, CollinsPJ, et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg, 1982; 69:655–657.
15.
RoerigJL, SteffenK, ZimmermanC, MitchellJE, CrosbyRD, CaoL. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis, 2012; 8:62–66.
16.
RoerigJL, SteffenKJ, ZimmermanC, MitchellJE, CrosbyRD, CaoL. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol, 2013; 33:479–484.
17.
HamadGG, HelselJC, PerelJM, et al.The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry, 2012; 169:256–263.
18.
KasimNA, WhitehouseM, RamachandranC, et al.Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm, 2004; 1:85–96.
BhamidipatiS. NDA 200-603 Latuda (Lurasidone Hydrochloride) Tablets, 40 and 80 mg, Sunovion Pharmaceuticals, Inc. Center for Drug Evaluation and Research: U.S. Food and Drug Administration, 2010.
22.
Food and Drug Administration. Center for Drug Evaluation and Research, Approval Package For: Application Number 21-168, Clinical Pharmacology and Biopharmaceutics Review. U.S. Food and Drug Administration, 2000.
23.
Food and Drug Administration. Center for Drug Evaluation and Research, Application Number: 21-729: Clinical Pharmacology and Biopharmaceutics Review(s). U.S. Food and Drug Administration, 2006.
24.
Food and Drug Administration. Center for Drug Evaluation and Research, Application Number: 200603, Pharmacology Review(s). U.S. Food and Drug Administration, 2010.
DarwichAS, PadeD, AmmoriBJ, JameiM, AshcroftDM, Rostami-HodjeganA. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between Cyp3a gut wall metabolism, permeability and dissolution. J Pharm Pharmacol, 2012; 64:1008–10024.
27.
DarwichAS, PadeD, Rowland-YeoK, et al.Evaluation of an in silico Pbpk post-bariatric surgery model through simulating oral drug bioavailability of atorvastatin and cyclosporine. CPT Pharmacometrics Syst Pharmacol, 2013; 2:e47.
